Bio-Rad Laboratories has expanded its Vericheck ddPCR™ product line with kits tailored for AAV2 and AAV8 serotypes. Designed for use with Bio-Rad’s Droplet Digital™ PCR Systems, these kits deliver unparalleled precision and reproducibility for critical quality attribute (CQA) assessment in AAV vector production.
AAV2’s prevalence in clinical trials and AAV8’s specialized role in liver-targeted therapies highlight the importance of accurate characterization. These new kits join the existing AAV5 and AAV9 kits, supporting gene therapy development for over 70% of the market.
Benefits for lab managers
- Improved Throughput: Streamline workflows with absolute quantification of full and empty capsids.
- Regulatory Compliance: Generate robust data aligned with regulatory standards.
- Resource Efficiency: Use minimal sample volumes for reliable results.
- Flexibility: Analyze purified or crude lysate samples with consistent accuracy.
- Tailored Solutions: Address specific therapeutic goals with support for the four most common AAV serotypes.
Bio-Rad’s Vericheck ddPCR™ kits allow labs to enhance productivity, ensure compliance, and confidently support groundbreaking gene therapy research.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: "Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization"
